Illustration of amyloid plaques (orange) among brain cellsScience Photo Library/Alamy
In early July, the US Food and Drug Administration (FDA) approved a treatment called donanemab for people with early-stage Alzheimer’s disease. It is the second drug shown to slow the condition’s progression, and the third FDA-authorised medication that clears the amyloid proteins that accumulate in the brains of people with Alzheimer’s.
The FDA’s approval of three new drugs – donanemab, lecanemab and aducanumab – in just over three years has led some to declare a leap forward in Alzheimer’s disease treatment. Japan, South Korea, China,…
The truth about the new class of Alzheimer’s drugs
Related Posts
Tamil Nadu: Why hundreds of Samsung workers are protesting in India
ReutersMore than a thousand workers are participating in the strikeFor the past 11 days, about 1,500 workers of South Korean technology giant Samsung Electronics have been striking work in the…
Trump becomes first president to pay in Bitcoin: ‘Very easy’
Former President Donald Trump made history as the first US president to ever pay in Bitcoin at PubKey, a NYC Bitcoin bar. “I just made the first transaction in Bitcoin,”…